EVENTS | VIEW CALENDAR
Weill Cornell, NewYork-Presbyterian establish the Institute for Precision Medicine
NEW YORK—Weill Cornell Medical College and NewYork-Presbyterian Hospital have announced the establishment of the Institute for Precision Medicine at Weill Cornell and NewYork-Presbyterian/Weill Cornell Medical Center. The translational medicine research institute will explore the boundaries of precision medicine and individualized treatments, looking to genomics to tailor therapies.
Dr. Mark Rubin, current vice chair for experimental pathology and director of Translational Research Laboratory Services at Weill Cornell, will lead the new institute. Rubin—who is also the Homer T. Hirst III Professor of Oncology, professor of pathology and laboratory medicine and professor of pathology in urology at Weill Cornell and a pathologist at NewYork-Presbyterian/Weill Cornell—is a leading pathologist and expert in prostate cancer with experience in using whole genomic sequencing in the lab to investigate DNA mutations.
"Precision medicine is the future of medicine, and its application will help countless patients," Dr. Laurie H. Glimcher, the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College, said in a press release. "The Institute for Precision Medicine, with Dr. Rubin's expertise and strong leadership, will accelerate our understanding of the human genome, provide key insights into the causes of disease and enable our physician-scientists to translate this knowledge from the lab to the clinical setting to help deliver personalized treatments to the sickest of our patients."
The science team at the Institute for Precision Medicine will work to establish a new treatment paradigm, from the "one-size-fits-all" approach to more targeted, individualized care, by identifying genetic influencers of each patient 's illness and using the information to more specifically target those contributing factors. This closer analysis will also allow researchers and physicians to treat patients with advanced diseases and those with drug resistance who are no longer responding to treatment.
The institute's work will hinge primarily on genomics sequencing, biobanking and bioinformatics. The two organizations will invest in state-of-the-art sequencing technology, as well as a larger biobank for patient specimens and samples. In addition, Weill Cornell and NewYork-Presbyterian will establish a team of bioinformaticians to analyze the gathered patient data and identify genetic mutations and other abnormalities.
"This institute will revolutionize the way we treat disease, linking cutting-edge research and next-generation sequencing in the laboratory to the patient's bedside. We will use advanced technology and the collective wealth of knowledge from our clinicians, basic scientists, pathologists, molecular biologists and computational biologists to pinpoint the molecular underpinnings of disease — information that will spur the discovery of novel treatments and therapies," said Rubin in a statement. "It's an exciting time to be involved in precision medicine and I look forward to advancing this game-changing field of medicine."
The Institute for Precision Medicine will also dedicate part of its focus to preventive precision medicine, as genomic sequencing can alert physicians to preexisting conditions or health issues that their patients are predisposed to developing.
"The Institute for Precision Medicine will enable our doctors to tailor effective treatments for individual patients and also predict the diseases that are likely to affect a patient long before they develop," Dr. Steven J. Corwin, CEO of NewYork-Presbyterian Hospital, said in a press release. "By harnessing the full potential of our enhanced understanding of the human genome, and extending its reach into the clinical realm, the institute will transform patient care at NewYork-Presbyterian/Weill Cornell Medical Center and beyond."
SOURCE: Weill Cornell press release